依达拉奉联合奥扎格雷钠治疗老年糖尿病并发急性脑梗死的临床评估

Clinic research on the therapeutic effect and safety of edaravone combined with sodiumozagrel in senile diabetic mellitus patients with acute cerebral infarction

目的 分析研究依达拉奉联合奥扎格雷钠治疗2型老年糖尿病并发急性脑梗死的临床疗效和安全性.方法 2010年1月至2011年1月河南省商丘市第一人民医院将68例以往确诊2型糖尿病再并发急性脑梗死的老年患者根据治疗适应证和家属意见分为两组,治疗组(34例)患者接受依达拉奉联合奥扎格雷钠治疗,对照组(34例)患者仅给予奥扎格雷钠治疗;治疗组34例,其中男21例,女13例;年龄60~81岁,平均67.8岁;既往有糖尿病史3~16年,合并高血压11例,血脂异常9例,冠心病7例.对照组34例,男22例,女12例;年龄60~80岁,平均67.5岁;有糖尿病史3~17年,合并高血压10例,血脂异常7例,冠心病8例,两组均有不同程度肢体瘫痪,且性别、年龄、并发症、病程及病情轻重基本相似,差异无统计学意义,具有可比性(P>0.05).两组患者分别在治疗前,治疗后1、2、3周,采用日常生活能力(ADL)量表、欧洲卒中评分(ESS)等神经心理分析工具对患者的疗效进行评价.计量资料用(x±s)表示,行t检验,以P<0.05为差异有统计学意义.结果 治疗组治疗前ESS评分(64.11±16.74)分,对照组(64.89±16.28)分,治疗后3周治疗组ESS评分为(78.94±13.07)分.对照组为(69.11±14.03)分;治疗组治疗前ADL评分(27.83±20.61)分,对照组(29.63±19.08)分,治疗后3周,治疗组为(72.99±21.07)分,对照组为(63.22±19.58)分.治疗后治疗组患者ESS和ADL评分均高于对照组(tESS= 2.988,tADL=1.982,P均<0.05).两组均无严重不良反应发生.结论 依达拉奉联合奥扎格雷钠治疗老年糖尿病并发急性脑梗死疗效显著,无明显不良反应,可明显提高患者的生活质量,值得临床推广应用.

Objective To evaluate the therapeutic effects and safety of edaravone combined with sodiumozagrel on senile diabetic mellitus patients with acute cerebral infarction.Methods From January 2010 to January 2011 First People''s Hospital of Shangqiu City, Henan Province in the past 68 patients diagnosed with type 2 diabetes and then acute cerebral infarction in elderly patients were divided into two groups, the treatment group (34 families according to treatment indications and comments patients) underwent ozagrel edaravone treatment, the control group (34 cases) were given only ozagrel treatment; treatment group, 34 cases, including 21 males and 13 females; aged 60 to 81 years old, average 67.8 years old; a history of diabetes, history of 3 to 16 years, 11 cases of hypertension, dyslipidemia nine cases, seven cases of coronary heart disease. The control group of 34 patients, 22 males and 12 females; aged 60 to 80 years, mean 67.5 years; there is a history of diabetes from 3 to 17 years, 10 cases of hypertension, dyslipidemia 7 cases, 8 cases of coronary heart disease in both groups There are varying degrees of paralysis, and the sex, age, complications, duration and severity were similar, the difference was not statistically signiifcant, comparable (P> 0.05). Two groups of patients were obtained before and after treatment 1,2,3 weeks, using the activities of daily living (ADL) scale, the European Stroke Scale (ESS) and other neuropsychological analysis tools to evaluate the efifcacy of the patient. Measurement data (x±s) that the t-test, with P <0.05 was considered statistically signiifcant.Results Before treatment, ESS score (64.11 ± 16.74) points, the control group (64.89 ± 16.28) points, after three weeks of treatment ESS scores for the treatment group (78.94 ± 13.07) points. The control group (69.11 ± 14.03) points; ADL score before treatment (27.83 ± 20.61) points, the control group (29.63 ± 19.08) points, three weeks after treatment, the treatment group (72.99 ± 21.07) points, the control group (63.22 ± 19.58) points. After treatment, patients treated with ESS and ADL scores were higher (tESS= 2.988, tADL=1.982,P<0.05). There were no serious adverse events. Conclusions The edaravone combined with sodiumozagrel treatment of senile diabetic mellitus patients with acute cerebral infarct is better than therapeutic use sodiumozagrel treatment,has fewer side effects, obviously improve the life quality of patients and it is worth to application at clinical.